s compared with the 2008 first half. The 2% increase, excluding the impact of foreign exchange, was primarily due to higher sales of Wyeth's key pharmaceutical franchises Prevnar,( )Enbrel (outside the U.S. and Canada) and Nutritional products, along with higher sales of Pristiq, the Protonix family,
Tygacil( )and Torisel. These increases were partially offset by decreased sales of Effexor due primarily to increased generic competition in international markets and lower Enbrel alliance revenue. Excluding the impact of foreign exchange, net revenue for the 2009 first half for the Pharmaceuticals and Animal Health segments increased 2% and 6%, respectively, while Consumer Healthcare was comparable to the 2008 first half.
Gross margin, as a percentage of net revenue, excluding certain significant items, increased 1.2 percentage points to 74.3% for the 2009 first half from 73.1% for the 2008 first half. The increase was primarily due to the impact of foreign exchange rates and favorable manufacturing variances during the 2009 first half.
Selling, general and administrative expenses, excluding certain significant items, decreased 7% for the 2009 first half versus the 2008 first half and were comparable to the 2008 first half, excluding the impact of foreign exchange, as cost savings related to the Company's productivity initiatives were offset by increased pension expense.
Research and development expenses, excluding certain significant items, were comparable for the 2009 first half versus the 2008 first half and increased 2%, excluding the impact of foreign exchange. The increase, excluding the impact of foreign exchange, was primarily due to increased clinical trial spending, including oncology projects and Prevnar 13 adult.
Interest expense, net was $148.3 million for the 2009 first half as compared with interest income, net of $8.8 million for the 2008 first half. ThiPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine news :1
. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures2
. Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men3
. Wyeths Prevenar 13* Receives First Approval4
. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products5
. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders6
. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market7
. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project8
. DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 9
. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care10
. U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth11
. Wyeth Reports Earnings Results for the 2009 First Quarter